Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000078884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of rasburicase 4.5 mg in the treatment of tumor lysis syndrome-related hyperuricemia.
Am J Health Syst Pharm
December 2024
The Ohio State University College of Pharmacy, Columbus, OH, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFOptimizing gout treatment: A comprehensive review of current and emerging uricosurics.
Joint Bone Spine
November 2024
Division of Rheumatology, Department of Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, 84132 Utah, United States; Department of Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, 84132 Utah, United States.
Gout is the most common inflammatory arthritis, affecting approximately 5.1% of adults in the United States (US) population. Gout is a metabolic and autoinflammatory disease.
View Article and Find Full Text PDFEnteral tube administration of extemporaneously compounded suspensions of venetoclax according to an institutional medication use process.
J Oncol Pharm Pract
November 2024
Oregon Health and Science University Hospital and Clinics, Portland, OR, USA.
Introduction: Venetoclax is a potent oral oncology drug (OOD) frequently used to treat hematologic cancers due to its convenience and high efficacy. However, some patients cannot tolerate solid oral formulations, requiring a reformulated version of venetoclax for effective administration. Currently, there is limited information in the literature regarding the extemporaneous compounding of venetoclax.
View Article and Find Full Text PDFEffectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice.
Cancer Rep (Hoboken)
October 2024
Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva and Swiss Cancer Center Leman, Geneva, Switzerland.
Background: Tumor lysis syndrome (TLS) is a potentially life-threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through hyperhydration, urate-lowering treatments, and a steroid prophase strategy.
Aims: This study aims to explore the impact of fractionated rituximab, an anti-CD20 antibody, on the occurrence and severity of TLS during the initial cycle in patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL).
Tumour lysis syndrome.
Nat Rev Dis Primers
August 2024
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Article Synopsis
- - Tumour lysis syndrome (TLS) is a serious medical emergency that occurs when cancer cells break down rapidly, releasing their contents into the bloodstream, which can lead to severe electrolyte imbalances and potential organ failure.
- - Common complications of TLS include high levels of uric acid, potassium, and phosphate, as well as low calcium levels, which can affect kidney function and increase the risk of seizures or even death.
- - Prevention involves careful monitoring and hydration to protect kidney health, and treatments may include medications like rasburicase and allopurinol to manage uric acid levels, though the role of xanthine measurement during treatment is still being researched.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!